Real-World Effectiveness of Risankizumab in Crohn's Disease: Outcome Data for an IL-23 Inhibitor from the Middle East.
This first Middle Eastern real-world study confirms risankizumab is effective and safe for complex CD and supports its use across different treatment lines.
Authors
- Mohamed Nasir Alzaabi (ORCID: https://orcid.org/0000-0002-6992-0708)
- Krishan Kumar (ORCID: https://orcid.org/0000-0001-5587-8687)
- Talha A. Malik (ORCID: https://orcid.org/0000-0002-6440-6064)
- Maryam Alahmad
- Thaer Khaleel Swaid
- Esraa Ahmed (ORCID: https://orcid.org/0009-0001-0661-8130)
- N M Omar
- H.A. Ahmed
- MN Quraishi (ORCID: https://orcid.org/0009-0004-1673-7792)
Institutions
- Khalifa University of Science and Technology (AE)
- Sheikh Shakhbout Medical City (AE)
- Cancer Research UK Clinical Trials Unit (GB)
- University of Birmingham (GB)
Publication Details
- Journal
- PubMed
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1093/crocol/otaf062
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00